Clinical trials located in

Manchester

Manchester city is located in United Kingdom. Currently, 20 clinical trials are being conducted in this city.

Manchester, located in the northwest of England, is renowned for its significant role in the Industrial Revolution, earning it the nickname “Cottonopolis” due to its plethora of cotton mills. This city is also celebrated for its vibrant music scene, having birthed legendary bands like The Smiths and Oasis. Manchester boasts two Premier League football teams, Manchester United and Manchester City, highlighting its deep-rooted sports culture. Additionally, it is home to the University of Manchester, a member of the prestigious Russell Group, known for its research achievements, including the isolation of graphene.

  • CT-EU-00119402

    Study of infigratinib in children with achondroplasia

    The clinical study involves children with achondroplasia who previously participated in the PROPEL study. The study evaluates infigratinib, an oral tablet medication. The goal is to assess the safety, tolerance, and effectiveness of the drug. Infigratinib targets the fibroblast growth factor receptor (FGFR), which is crucial in processes like cell growth, wound healing, and bone and blood vessel formation.

    The study is aimed at children aged 3 to 11 years who can walk unaided and take oral medication. Various doses will be adjusted based on the child’s weight. The study will assess changes in annual height growth, pharmacokinetic parameters (such as maximum drug concentration in the blood), and any adverse events. Additionally, changes in body proportions, limb length, and other growth measures will be analyzed.

    • Infigratinib
  • Testing Vemurafenib and Cobimetinib for BRAF Positive Cancers

    This clinical trial is for patients with cancers that have a specific change in their cancer cells known as BRAF V600 mutation. It uses two drugs, vemurafenib and cobimetinib, to see if they can effectively treat various types of cancers such as solid tumors, haematological malignancies, melanoma, thyroid cancer, ovarian neoplasms, colorectal neoplasms, laryngeal neoplasms, non-small-cell lung carcinoma, glioma, multiple myeloma, and Erdheim-Chester disease. The purpose of this study is to determine if these drugs can help treat cancers with the BRAF V600 mutation.

    In the study, participants will receive both drugs until their disease progresses, they experience unacceptable side effects, or they decide to withdraw. Blood samples will be collected at different times during the treatment for research purposes. Participants will be monitored every three months for two years after completing the treatment.

    • Vemurafenib
    • Cobimetinib
  • Study of R3R01 for Kidney Conditions: Alport Syndrome and FSGS

    This study focuses on treating Alport Syndrome and Focal Segmental Glomerulosclerosis (FSGS), which are both kidney diseases. The therapy being tested uses a drug called R3R01.

    The study aims to determine if R3R01 can improve kidney function and reduce damage in patients with these conditions. Participants will receive R3R01 for 12 weeks, and researchers will observe the changes in protein levels in their urine, kidney function, and any side effects. This study is designed to evaluate the safety, tolerability, and effectiveness of R3R01 in these patients.

    • R3R01
  • Study on the safety and effectiveness of Setanaxib for Alport Syndrome patients

    The purpose of this study is to learn about the safety and tolerability of a drug called setanaxib in patients with Alport syndrome, when added to their standard of care treatment. The study will compare how safe setanaxib is when compared to a placebo. Participants will be asked about any side effects they experience at each study visit. Additionally, tests in blood, urine, and other examinations will be used to assess the safety of setanaxib. The study will also measure how well setanaxib works in comparison to a placebo by measuring urine protein and certain markers in the blood and urine. The concentration of setanaxib in the blood will also be measured throughout the course of the study.

    This is a Phase 2a, randomized, double-blind, placebo-controlled study. This means that participants will be randomly assigned to receive either setanaxib or a placebo, and neither the participants nor the researchers will know who is receiving which treatment.

    • placebo
    • Setanaxib
  • Long-term safety and efficacy study of PTC518 for Huntington’s disease

    This study focuses on Huntington’s Disease and evaluates the long-term safety and effectiveness of the drug PTC518. Participants, who have previously completed related study phases, will continue taking PTC518 in doses of 5, 10, or 20 milligrams. The study aims to monitor the safety of long-term use and assess how the drug impacts biological markers and symptoms of the disease over a period of 30 months. This is an extension study where all participants will receive the active drug, ensuring continuous monitoring and evaluation of its effects.

    • PTC518
  • Study comparing INBRX-101 and Zemaira for Alpha-1 Antitrypsin Deficiency-Related Emphysema

    This clinical study focuses on Alpha-1 Antitrypsin Deficiency (AATD), a genetic condition that can lead to lung diseases such as emphysema. AATD is caused by low levels of the protein alpha-1 antitrypsin (AAT), which helps protect the lungs from damage.

    The study compares two treatments: INBRX-101, a new investigational drug, and a standard therapy using plasma-derived Alpha1-Proteinase Inhibitor (A1PI), commonly known as Zemaira. INBRX-101 is designed to maintain higher and more stable levels of AAT in the blood than current treatments, potentially providing better protection for the lungs over time.

    The purpose of the study is to evaluate the effectiveness, safety, and how the body processes these treatments. Participants will receive either INBRX-101 or the standard A1PI therapy, with neither the participants nor the doctors knowing which treatment each person is getting (this is called a double-blind study).

    Participants will go through a screening phase to ensure they meet the study criteria. If they are currently on other A1PI therapies, they will need a break period (washout phase) before starting the treatment phase, which lasts about 32 weeks. During this time, participants will receive their assigned treatment regularly and undergo various health assessments, including blood and urine tests, lung function tests, and imaging studies like CT scans. The study will also include some additional sub-studies to gather more detailed data on how the treatments work in the body.

    The study aims to gather important information that could lead to better treatment options for people with AATD and related lung diseases. It will help determine if INBRX-101 offers a significant improvement over the current standard treatment.

    • INBRX-101
    • Zemaira
  • A study on the use of the new drug NX-1607 for patients with advanced types of various cancers

    The main goal of this study is to test the safety and effectiveness of a new drug called NX-1607 in the treatment of various types of advanced cancers. NX-1607 is taken orally and works by blocking a protein called Cbl-b.

    The study consists of two parts. The first part, called Phase 1a, will study different doses of NX-1607 alone or in combination with paclitaxel to find the highest safe dose. This section includes patients with cancers such as ovarian, stomach, head and neck, melanoma, lung, prostate, mesothelioma, breast, bladder, cervical, colorectal and lymphoma.

    In the second part, called Phase 1b, selected doses from Phase 1a will be administered to separate groups of patients with the same type of cancer. The main goal is to see if NX-1607, alone or with paclitaxel, can shrink or control tumors. Patient safety will be continuously monitored by researchers.

    The goal of this study is to find the right dose of the experimental drug NX-1607 and see if it has promising anti-cancer effects in a variety of advanced cancers for which treatment options are limited. Patient safety is the highest priority throughout the entire examination.

    • NX-1607
    • Paclitaxel
  • Tebentafusp for the treatment of recurrent melanoma

    The study aims to investigate a new treatment for patients with cutaneous melanoma or uveal melanoma after surgery. Researchers want to see if a new drug called tebentafusp can help these patients live longer.

    Tebentafusp is a new drug that has already been studied in patients with advanced melanoma of the skin and uvea. In this study, this medicine will be administered to patients whose disease has relapsed at the molecular level using a special blood test. Patients will receive tebentafusp for up to 6 months as an intravenous infusion once a week and will then be followed for 12 months to check whether the disease has returned.

    • tebentafusp
  • Study of Fidrisertib/IPN60130 in the treatment of Fibrodysplasia Ossificans Progressiva (FOP)

    The aim of this study is to test a new drug called fidrisertib (also known as IPN60130) to treat a rare disease called Fibrodysplasia Ossificans Progressiva, or FOP. FOP is a grave disease that causes bones to start growing in places they shouldn’t, such as muscles and soft tissues. This causes a lot of pain, swelling, and stiffness in the joints, making movement difficult.

    In the study, some participants will be given the new drug fidrisertib at two different doses, and others will be given a dummy treatment called a placebo. Researchers will monitor the situation closely, performing special tests called low-dose whole-body computed tomography (WBCT) to measure new bone growth. For some older participants, they may also use another type of test called fluorine-18-labeled sodium fluoride positron emission tomography – computed tomography to check bone growth.

    • IPN60130
    • placebo
  • NCT05091346

    This here clinical trial is aimin’ to test out a new combination of drugs for treatin’ some tough cancers. The main drugs bein’ studied are E7386, a newfangled tablet, and pembrolizumab, which is given through an IV drip. For folks with liver cancer, they might also get lenvatinib capsules added to the mix.

    The first part of the trial is focused on findin’ the right doses of E7386 to use with pembrolizumab, makin’ sure the combination is safe and tolerable for patients. The doc’s will be keepin’ a close eye on any serious side effects durin’ this phase.

    If the doses look good, the second part will test how well this drug combo actually works against melanoma (skin cancer), colorectal cancer (cancer of the colon or rectum), and hepatocellular carcinoma (liver cancer). The main thing they’ll be measurin’ is the objective response rate, which means how many folks see their tumors shrinkin’ or disappearin’ altogether with this treatment.

    So in a nutshell, this trial is aimin’ to find a new, effective way to fight some of the toughest cancers out there usin’ a novel combination of medicines. If you’re interested in joinin’, be sure to ask your doctor about all the risks and benefits involved.

    • E7386
    • Lenvatinib
    • Pembrolizumab
  • Study of melanoma patients using cell therapy – ATL001

    This is a study to test a cell therapy called ATL001 in melanoma patients. ATL001 consists of immune cells taken from the patient that can recognize and attack cancer cells. The study consists of two parts:

    First, part of the cancer tissue will be removed to produce ATL001 specifically for the patient. The subject will then receive chemotherapy to temporarily suppress the immune system before being infused with ATL001 cells. This makes it easier for ATL001 cells to find and fight cancer cells.

    The main goal is to evaluate the safety of ATL001 and any side effects that may occur. The study will also test whether ATL001 can help shrink or control melanoma. The patient will be monitored closely for 24 months after receiving ATL001, and then followed for at least 5 years to detect any long-term effects.

    • Niwolumab
    • ATL001
  • Study of the drug combination mRNA-4157/V940 and Pembrolizumab in the treatment of melanoma

    The aim of this clinical trial is to test whether a new drug called mRNA-4157/V940 in combination with pembrolizumab can help prevent the recurrence of melanoma in people who have already had it. Currently, mRNA-4157/V940 is what is called “individualized neoantigen therapy,” which means it is a therapy created specifically for each patient based on their cancer cells. Doctors give this drug along with pembrolizumab, a drug that helps the immune system fight cancer cells.

    The main goal of this study is to determine whether taking V940 and pembrolizumab together is more effective in preventing melanoma recurrence than taking pembrolizumab alone. Researchers will closely monitor how long it takes for the cancer to return or spread. The study will last for approximately 74 months.

    • mRNA-4157/V940
    • placebo
    • Pembrolizumab
  • Study on the Safety and Effectiveness of INCB057643 for Myelofibrosis and Other Myeloid Neoplasms

    This clinical trial is focused on evaluating the safety, tolerability, and initial effectiveness of a medication called INCB057643, either on its own or in combination with another drug known as ruxolitinib. It is designed for participants who are dealing with myelofibrosis or other advanced myeloid neoplasms, which are types of blood disorders. The study aims to understand how well participants can handle the treatment and to observe any potential benefits or side effects that may occur during the trial. The treatment’s impact will be measured by monitoring the number of treatment-related adverse events, which includes any new or worsening symptoms following the start of the medication. This study is an important step towards finding new treatment options for individuals with myelofibrosis and related conditions, offering hope for better management of these diseases.

    • INCB057643
    • Ruxolitinib
  • Exploring a new vaccine regimen with Ipilimumab for myeloproliferative neoplasms

    This clinical trial is focused on evaluating the safety of a new treatment regimen for myeloproliferative neoplasms (MPNs), a type of blood disorder. The treatment involves **VAC85135**, a neoantigen vaccine, which will be given alongside **Ipilimumab**, a medication administered through an IV infusion. The main goal of this study is to understand how safe this combination is for patients with MPNs.

    This study is in its Phase 1, which means it’s the first time this treatment is being tested in people, with the main focus on safety. The trial will start by assessing the participants from the first day of receiving the treatment and will continue to monitor them for up to 79 weeks to capture any potential side effects that may occur.

    • VAC85135
    • Ipilimumab
  • Exploring the Impact of ATL1102 in Boys with Duchenne Muscular Dystrophy

    This study is designed to test the effectiveness and safety of a new treatment called ATL1102. The trial is specifically for boys aged 10 to <18 who cannot walk (non-ambulatory).

    The study is divided into two main parts. In the first part, participants will be randomly assigned to receive either ATL1102 at doses of 25 mg or 50 mg, or a placebo (a treatment with no active drug), given as a weekly subcutaneous injection. This phase will last for 24 weeks and is double-blind, meaning neither the participants nor the researchers will know who is receiving the actual drug or the placebo.

    Following this, all participants will move into the second part of the study, where they will receive ATL1102 for another 24 weeks. This part is open-label, which means everyone will know they are receiving the active drug.

    The main goal of the study is to see how well ATL1102 can improve upper limb strength, which is crucial for daily activities. This will be measured using the Performance of Upper Limb (PUL) 2.0 score, a tool designed to assess upper limb strength in individuals with DMD.

    • ALT1102
  • Sparsentan treatment study for children with Kidney Diseases

    This study involves children with kidney diseases that lead to high levels of protein in the urine. These diseases include Focal Segmental Glomerulosclerosis (FSGS), Minimal Change Disease (MCD), Immunoglobulin A Nephropathy (IgAN), Immunoglobulin A Vasculitis (IgAV), and Alport Syndrome (AS). The study will use a drug called Sparsentan, administered as an oral suspension or tablet.

    The goal is to determine if Sparsentan is safe and effective for these children. Participants will receive Sparsentan for 112 weeks, and their progress will be monitored to see if protein levels in their urine decrease and if their overall health improves. The study is open-label, meaning all participants will know they are receiving the drug.

    • Sparsentan
  • Evaluating new medication in congenital hyperinsulinism treatment

    This clinical trial is focused on testing a new treatment called HM15136 for individuals aged 2 years and older who have Congenital Hyperinsulinism (CHI). CHI is a condition that causes persistent low blood sugar levels due to excessive insulin production. The study aims to find out how safe and effective HM15136 is when used alongside standard treatments that participants are already receiving for CHI.

    HM15136 will be given as a subcutaneous (under the skin) injection once a week for 8 weeks. The trial will look into how well the body tolerates this medication, any side effects that might occur, and how the body processes the drug. Additionally, the study will assess the effectiveness of HM15136 in managing blood sugar levels in participants.

    The safety of the participants will be closely monitored throughout the study, focusing on any adverse events, serious adverse events, and changes in clinical laboratory tests. The trial will also measure the highest concentration of the drug in the bloodstream and how long it takes to reach this peak level after administration.

    This study is an opportunity for individuals with CHI to potentially improve their condition and contribute to medical research in finding new treatments for this rare disease.

    • HM15136
  • CT-EU-00091440

    Investigating new drug, JNJ-75276617 for the treatment of patients with acute leukemia

    This study is about a new medicine called JNJ-75276617, designed to help patients with a type of blood cancer called Acute Leukemia. Acute leukemia is an illness where the bone marrow makes too many white blood cells that are abnormal. This study is divided into two parts: first, to figure out the best dose of the new medicine, and second, to check if it’s safe at that dose. For up to 2 years and 10 months, researchers will follow participants closely and check for any changes in their health. They will look at the number of participants who experience bad side effects, how much of the drug is in their bodies, and how the disease is responding to the new medicine. The main goal is to find a dose of the drug that’s both safe and can possibly help patients with acute leukemia.

    • JNJ-75276617- new potential treatment for Acute myeloid leukemia
  • Testing a new drug for advanced prostate cancer

    This trial compares a new drug called AZD5305 with a placebo in men who have a specific kind of prostate cancer that has not responded to usual treatment methods. It’s a large trial, with around 1800 participants, and the main aim is to see whether the new treatment can help slow down the disease for longer than current treatments. Participants will be assigned to two different groups, and they will not know whether they’re receiving the real drug or the placebo. Their health will be monitored closely, with regular scans to check the progress of the cancer. The trial will also look at any side effects of the treatment and how it affects the patients’ ability to do their daily activities.

    • Enzalutamide/Xtandi
    • Darolutamide/Nubequa
    • Abiraterone Acetate/Zytiga
    • Saruparib
  • Research to enhance cancer treatments for kids and teens

    This clinical trial, known as CAMPFIRE, encompasses several studies testing new drugs for children and young adults with cancer. It includes various drug combinations such as Ramucirumab, Cyclophosphamide, Vinorelbine, Gemcitabine, Docetaxel, Abemaciclib, Irinotecan, and Temozolomide. These trials aim to evaluate the safety and effectiveness of these drugs in treating different cancer types. The study is interventional, with an estimated enrollment of 105 participants, randomized in parallel assignment. The primary purpose is treatment-focused.

    • Abemaciclib
    • Temozolomide
    • Irinotecan
    • Ramucirumab
    • Gemcitabine
    • Vinorelbine
    • Cyclophosphamide
    • Docetaxel

See more clinical trials in other cities in United Kingdom:

.